{"product_id":"exelixis-business-model-canvas","title":"Exelixis Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExelixis's Business Model Unveiled\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Exelixis's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape. Ideal for entrepreneurs, consultants, and investors looking for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Companies for Co-development and Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis actively pursues key partnerships with other pharmaceutical giants to co-develop and globally commercialize its promising oncology pipeline. These collaborations are crucial for expanding market access and sharing the significant financial burden of late-stage drug development and widespread distribution.\u003c\/p\u003e\n\u003cp\u003eNotable examples include its agreements with Ipsen Pharma SAS and Takeda Pharmaceutical Company Limited for cabozantinib, a tyrosine kinase inhibitor. These alliances allow Exelixis to leverage its partners' established global networks and expertise, accelerating the reach of its innovative cancer therapies to patients worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis actively collaborates with leading academic and research institutions to drive innovation in oncology. These partnerships are vital for accessing novel scientific insights and early-stage research, which are foundational to identifying promising new drug candidates.\u003c\/p\u003e\n\u003cp\u003eFor instance, in 2024, Exelixis continued its engagement with various university research programs, focusing on understanding complex cancer biology and identifying new therapeutic targets. These collaborations often involve joint research projects and the exchange of scientific expertise, accelerating the pace of discovery.\u003c\/p\u003e\n\u003cp\u003eThese academic alliances provide Exelixis with access to specialized scientific knowledge and cutting-edge technologies that might not be available internally. This synergistic approach is critical for navigating the intricate landscape of drug development and bringing innovative treatments to patients faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis leverages Contract Research Organizations (CROs) to manage and execute crucial aspects of its clinical trials.  These partnerships are vital for navigating the complexities of drug development, ensuring trials are conducted efficiently and adhere to strict regulatory standards.\u003c\/p\u003e\n\u003cp\u003eCROs offer specialized expertise in areas like clinical trial design, patient identification and enrollment, meticulous data collection, and the preparation of regulatory submissions. This outsourcing allows Exelixis to focus on its core competencies while benefiting from the CROs’ established infrastructure and experience.\u003c\/p\u003e\n\u003cp\u003eIn 2023, the global CRO market was valued at approximately $50 billion, with significant growth projected. Exelixis' strategic use of these organizations underscores the industry trend towards specialized outsourcing to accelerate drug development timelines and manage costs effectively.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExelixis' strategic alliances with healthcare providers and networks are fundamental to its business model, ensuring its innovative cancer therapies reach patients effectively. These collaborations with hospitals, specialized cancer treatment centers, and oncology practices are crucial for product distribution and seamless integration into patient care pathways.\u003c\/p\u003e\n\u003cp\u003eThese partnerships are not just about getting drugs to market; they are about ensuring that Exelixis’ treatments are adopted by the clinicians who are on the front lines of cancer care. This integration into clinical practice is key for patient access and ultimately for the success of their therapeutic offerings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHospital and Clinic Networks:\u003c\/strong\u003e Exelixis actively cultivates relationships with major hospital systems and cancer centers to facilitate the prescription and administration of its oncology drugs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOncology Practices:\u003c\/strong\u003e Direct engagement with independent and group oncology practices ensures broad reach within the specialized field of cancer treatment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Access Programs:\u003c\/strong\u003e These partnerships often extend to co-developing patient access programs, simplifying the process for patients to receive and afford necessary treatments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExelixis relies on key technology and supply chain partners to ensure its operations run smoothly and its medicines reach patients worldwide. Collaborations with technology providers, such as Kinaxis for advanced supply chain planning, are critical. This partnership helps optimize inventory management and forecasting, crucial for a biopharmaceutical company dealing with complex global logistics.\u003c\/p\u003e\n\u003cp\u003eManufacturing organizations are also vital partners, enabling the robust production of Exelixis's therapies. These relationships are fundamental to maintaining a consistent and reliable supply of products. By working closely with these entities, Exelixis can navigate the intricacies of drug manufacturing and distribution, ensuring timely delivery to meet patient needs.\u003c\/p\u003e\n\u003cp\u003eThese strategic alliances are not just about day-to-day operations; they are foundational to Exelixis's ability to scale and serve a growing patient population. The focus remains on building resilient supply chains that can adapt to market demands and regulatory requirements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eTechnology Partnerships:\u003c\/strong\u003e Exelixis leverages technology providers like Kinaxis for enhanced supply chain planning and visibility.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eManufacturing Collaborations:\u003c\/strong\u003e Partnerships with manufacturing organizations are essential for the consistent and high-quality production of its pharmaceutical products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Supply Chain Efficiency:\u003c\/strong\u003e These alliances are designed to ensure the efficient and timely distribution of medicines across global markets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships Drive Oncology Innovation and Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis' key partnerships extend to academic institutions, fostering early-stage research and target identification.  In 2024, these collaborations continued to focus on understanding complex cancer biology, crucial for discovering new drug candidates.\u003c\/p\u003e\n\u003cp\u003eStrategic alliances with pharmaceutical giants like Ipsen and Takeda are vital for co-development and global commercialization, leveraging their established networks.  These collaborations are essential for sharing development costs and expanding market access for Exelixis' oncology pipeline.\u003c\/p\u003e\n\u003cp\u003eThe company also relies on Contract Research Organizations (CROs) to manage clinical trials efficiently, a market valued at over $50 billion in 2023.  These partnerships ensure adherence to regulatory standards and accelerate drug development timelines.\u003c\/p\u003e\n\u003cp\u003eFurthermore, partnerships with healthcare providers and networks are critical for patient access and the integration of Exelixis' therapies into clinical practice.  Technology and manufacturing partners, such as Kinaxis for supply chain planning, are also fundamental to ensuring a consistent and reliable global supply.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003ePurpose\u003c\/th\u003e\n\u003cth\u003eKey Examples\/Focus\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmaceutical Giants\u003c\/td\u003e\n\u003ctd\u003eCo-development, Global Commercialization\u003c\/td\u003e\n\u003ctd\u003eIpsen, Takeda (for cabozantinib)\u003c\/td\u003e\n\u003ctd\u003eExpanded market access, shared financial burden\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\/Research Institutions\u003c\/td\u003e\n\u003ctd\u003eEarly-stage research, Target Identification\u003c\/td\u003e\n\u003ctd\u003eUniversity research programs (2024 focus)\u003c\/td\u003e\n\u003ctd\u003eAccess to novel scientific insights\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Research Organizations (CROs)\u003c\/td\u003e\n\u003ctd\u003eClinical Trial Management\u003c\/td\u003e\n\u003ctd\u003eSpecialized expertise in trial design, data collection\u003c\/td\u003e\n\u003ctd\u003eEfficient trials, regulatory adherence, accelerated timelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Providers\/Networks\u003c\/td\u003e\n\u003ctd\u003ePatient Access, Clinical Integration\u003c\/td\u003e\n\u003ctd\u003eHospitals, Cancer Centers, Oncology Practices\u003c\/td\u003e\n\u003ctd\u003eEffective drug prescription and administration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology\/Supply Chain Partners\u003c\/td\u003e\n\u003ctd\u003eSupply Chain Planning, Manufacturing\u003c\/td\u003e\n\u003ctd\u003eKinaxis (supply chain planning), Manufacturing Organizations\u003c\/td\u003e\n\u003ctd\u003eOptimized inventory, consistent product supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written business model tailored to Exelixis' strategy, focusing on developing and commercializing innovative cancer therapies.\u003c\/p\u003e\n\u003cp\u003eOrganized into 9 classic BMC blocks, it details customer segments (oncologists, patients), value propositions (novel treatments), and key activities (R\u0026amp;D, commercialization).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExelixis' Business Model Canvas provides a clear, structured approach to dissecting their oncology drug development strategy, offering a pain point reliever by quickly visualizing key resources and value propositions.\u003c\/p\u003e\n\u003cp\u003eThis concise snapshot helps teams rapidly understand Exelixis' core operations and market approach, easing the pain of complex strategic analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis’ core activity revolves around the discovery, development, and clinical advancement of innovative oncology medicines. This necessitates substantial R\u0026amp;D investment to pinpoint new molecular targets, create novel compounds, and execute preclinical and clinical trials for a broad spectrum of small molecules and biotherapeutics.\u003c\/p\u003e\n\u003cp\u003eIn fiscal year 2023, Exelixis reported R\u0026amp;D expenses of $758 million, highlighting a significant commitment to advancing its pipeline. This investment fuels the progression of its lead programs, such as XL518 (savolitinib) and numerous other candidates in various stages of clinical development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis's key activity is managing a robust pipeline of clinical trials. This includes crucial Phase 3 studies for promising drug candidates such as zanzalintinib. The company's focus is on meticulous trial design, efficient patient enrollment, rigorous data collection and analysis, and unwavering adherence to regulatory standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis actively navigates intricate regulatory pathways to obtain approvals for new drug indications and sustain existing product licenses. This is a critical function for market access and continued commercialization.\u003c\/p\u003e\n\u003cp\u003eA prime example of this key activity is Exelixis’ success in securing U.S. and European approvals for CABOMETYX in neuroendocrine tumors. These approvals, achieved in 2024, represent significant milestones in expanding the therapeutic reach of their oncology portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExelixis drives the commercialization of its key oncology treatments, CABOMETYX and COMETRIQ. In the U.S., this is managed through a direct sales force, while international markets rely on strategic partnerships. This dual approach ensures broad market reach for their therapies.\u003c\/p\u003e\n\u003cp\u003eThe company's commercialization efforts focus on robust marketing campaigns, efficient sales force management, and securing favorable market access for its products. These activities are critical for translating clinical success into commercial revenue and patient benefit.\u003c\/p\u003e\n\u003cp\u003eFor instance, in 2023, Exelixis reported net product revenue of $1.43 billion, with CABOMETYX being the primary driver. This highlights the effectiveness of their commercialization and sales strategies in generating significant financial returns and reaching a wide patient population.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDirect U.S. Sales:\u003c\/strong\u003e Exelixis employs its own sales teams to promote CABOMETYX and COMETRIQ within the United States.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInternational Partnerships:\u003c\/strong\u003e The company collaborates with global partners to distribute and market its therapies in various international regions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarketing and Market Access:\u003c\/strong\u003e Key activities include developing targeted marketing strategies and navigating regulatory and payer landscapes to ensure patient access.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Generation:\u003c\/strong\u003e In 2023, net product revenue reached $1.43 billion, underscoring the success of these commercialization efforts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExelixis actively manages its intellectual property, a critical activity for safeguarding its groundbreaking cancer therapies. This involves a proactive approach to patent litigation and defense, ensuring the exclusivity and market longevity of its innovations. For example, in 2023, Exelixis reported significant legal expenses related to patent defense, underscoring the importance of this function. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatent Protection:\u003c\/strong\u003e Exelixis’s core activity involves securing and defending patents for its novel drug candidates and their applications, crucial for maintaining market exclusivity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLitigation and Defense:\u003c\/strong\u003e The company engages in ongoing patent litigation and defense strategies to counter challenges and protect its revenue streams from generic competition.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Robust IP management ensures Exelixis maintains a strong competitive edge, allowing it to reinvest in research and development for future therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Realization:\u003c\/strong\u003e By protecting its innovations, Exelixis maximizes the long-term revenue potential of its approved products, such as cabozantinib.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDriving Oncology Innovation: From Discovery to Market Success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis's key activities are centered on the discovery, development, and commercialization of innovative cancer treatments. This includes rigorous research and development, navigating complex regulatory processes, and managing intellectual property to protect its innovations.\u003c\/p\u003e\n\u003cp\u003eThe company invests heavily in R\u0026amp;D, with $758 million spent in 2023, to advance its pipeline of small molecules and biotherapeutics, including promising candidates like zanzalintinib. Exelixis also focuses on securing regulatory approvals, such as the 2024 approvals for CABOMETYX in neuroendocrine tumors, and managing its intellectual property through patent defense.\u003c\/p\u003e\n\u003cp\u003eCommercialization is driven by a direct U.S. sales force and international partnerships, aiming to maximize market access and revenue. In 2023, net product revenue reached $1.43 billion, primarily from CABOMETYX, demonstrating the success of these commercialization strategies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Activity\u003c\/td\u003e\n\u003ctd\u003eDescription\u003c\/td\u003e\n\u003ctd\u003e2023 Financial Impact\u003c\/td\u003e\n\u003ctd\u003eKey 2024 Milestone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eDiscovery and clinical advancement of oncology medicines.\u003c\/td\u003e\n\u003ctd\u003e$758 million in R\u0026amp;D expenses.\u003c\/td\u003e\n\u003ctd\u003eProgression of XL518 (savolitinib) and other pipeline candidates.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003eSecuring approvals for new drug indications and licenses.\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eU.S. and European approvals for CABOMETYX in neuroendocrine tumors.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eMarketing and sales of key oncology treatments like CABOMETYX.\u003c\/td\u003e\n\u003ctd\u003e$1.43 billion in net product revenue.\u003c\/td\u003e\n\u003ctd\u003eContinued market penetration and sales growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntellectual Property Management\u003c\/td\u003e\n\u003ctd\u003eProtecting and defending patents for novel therapies.\u003c\/td\u003e\n\u003ctd\u003eSignificant legal expenses for patent defense.\u003c\/td\u003e\n\u003ctd\u003eMaintaining market exclusivity for key products.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas you are previewing is the exact document you will receive upon purchase. This is not a sample or mockup, but a direct representation of the comprehensive analysis that will be delivered to you. Upon completing your order, you will gain full access to this identical, ready-to-use Business Model Canvas, allowing you to immediately leverage its insights for your strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611272757625,"sku":"exelixis-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/exelixis-business-model-canvas.png?v=1754754237","url":"https:\/\/growthsharematrix.com\/products\/exelixis-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}